Leadless Pacemaker Market Size, Share, Growth, Forecast and Outlook (2024-2031)

Global Leadless Pacemaker Market is segmented By Type (Single Chamber, Dual Chamber) By Product (Micra Transcatheter Pacing System, Nanostim Leadless Pacemaker, Others) By Application (Atrial Fibrillation, Sinus Node Dysfunction, Bradycardia-tachycardia syndrome, Others) By End User (Hospital Pharmacies, Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Outpatient Facilities, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global Leadless Pacemaker market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

A leadless pacemaker is a medical device that is implanted right inside the heart without the implantation of leads in the heart or a separate battery under the heart. It comes with a lot of advantages when compared to conventional pacemakers such as reduced infection risk at the site, lead dislodgment, and blood clots.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Increasing Market Developments

Pacemaker systems have undergone rapid advancements such as increased battery life, reduced generator size, and other improvements that increased the efficiency of leadless pacemakers. Advancements in battery technologies, and the development of sophisticated devices.  

In July 2021, MicroPort, Cardiac Rhythm Management Limited (a subsidiary of Cardiac invested US$150 Million in the development of implantable devices and defibrillators. In addition, MicroPort CRM is currently developing a sub-cutaneous ICD (S-ICD) and a leadless pacemaker. In April 2022, Cairdac raised $18.5M in funding for developing a leadless pacemaker transcatheter system (ALPS) powered entirely using kinetic energy from the heart.

High incidence of battery malfunction

Failure of the device can be seen due to the battery malfunction. For instance, according to AHA journals organization, 2023, there was a high incidence of battery failure of the Nanostim LCP in a long time. More than 40% of devices failed after 3 years. Pacemaker battery depletion occurs due to inadequate follow-up procedures. Leadless pacemakers fail to integrate with defibrillator systems. 

Segment Analysis

The global leadless pacemaker market is segmented based on type, product, application end-user and region.

Dual-chamber type is Expected to Dominate the Market

A dual-chamber leadless pacemaker is used for a wider range of treatment options as it consists of 2 devices. An increase in approvals by the FDA is expected to drive the market in the forecast period. For instance, in May 2023, Medtronic plc received U.S. Food and Drug Administration (FDA) approval for its Micra AV2 and Micra VR2, the next generation of its industry-leading miniaturized, leadless pacemakers.

In July 2023, Abbott received the U.S. Food and Drug Administration (FDA) approval for the AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. 

In January 2022, Medtronic plc received regulatory approval from Japan's Ministry of Health, Labor, and Welfare for the sale and reimbursement of the Micra AV Transcatheter Pacing System (TPS).

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is expected to hold the largest share of the market due to the increase in cardiovascular diseases in the US and Canada. For instance, according to the American Heart Association, 2024, heart disease has been a leading cause of death for the past 100 years. Approximately, 46.7% of U.S. adults have high blood pressure. Yet, over 38% of those with high blood pressure are unaware that they have it. 

Furthermore, according to the Journal of Cardiac Failure, approximately 6.7 million Americans over 20 years of age have poor heart, and the prevalence of cardiac failure is expected to rise to 8.5 million Americans by 2030.

Key Developments

• In February 2022, Abbott released the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study.

Competitive Landscape

The major global players in the leadless pacemaker market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, MicroPort Scientific Corporation, EBR Systems, Inc, Biotronik, CAIRDAC, Lepu Medical Technology (Beijing)Co., Ltd., Nanostim Inc among others.

Why Purchase the Report?

• To visualize the global leadless pacemaker market segmentation based on type, product, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of leadless pacemaker market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global leadless pacemaker market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies